Laane-Tallinna Keskhaigla AS
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Laane‑Tallinna Keskhaigla AS researchers are investigating new approaches to prevent ischemic stroke and reduce the risk of systemic embolism in patients with atrial fibrillation. The studies aim to determine whether emerging anticoagulant agents can offer safer and more effective protection compared with existing treatments.
- Evaluation of novel anticoagulant efficacy
- Comparison with standard therapy for stroke prevention
- Assessment of major bleeding risk
- Long‑term safety outcomes in high‑risk patients
With a team of 11 investigators, the hospital conducts four cardiovascular trials that contribute valuable data to improve outcomes for individuals at risk of stroke.
Digestive System Diseases
The site also focuses on ulcerative colitis, testing innovative oral therapies designed to achieve clinical remission and maintain disease control. These studies seek to enhance treatment effectiveness while monitoring long‑term safety for patients with moderate to severe disease.
- Induction of clinical remission
- Maintenance of disease activity reduction
- Evaluation of long‑term safety profile
- Impact on patient quality of life
Through its four digestive‑system trials, the hospital provides important insights that may lead to better therapeutic options for those living with ulcerative colitis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 10 therapeutic areas and 15 of 81 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 81 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG4trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Laane-Tallinna Keskhaigla AS
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2) | Morphic Therapeutic Inc. | Phase II | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 81 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Golimumab | 2 | Unknown | 2022-11-30 | 2022-11-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.